Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dolasetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 8/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.86 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.86 |
| ▸ | HTR3E | A5X5Y0 | 7/20 | 0.64 |
| ▸ | HTR3B | O95264 | 7/20 | 0.64 |
| ▸ | HTR3D | Q70Z44 | 7/20 | 0.64 |
| ▸ | HTR3C | Q8WXA8 | 7/20 | 0.64 |
| ▸ | HTR1A | P08908 | 2/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.64 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.64 |
| ▸ | HTR1D | P28221 | 1/20 | 0.64 |
| ▸ | HTR1B | P28222 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HTR1E | P28566 | 1/20 | 0.64 |
| ▸ | HTR1F | P30939 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.64 |
| ▸ | HTR5A | P47898 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolasetron SCHEMBL5655022 | 1.00 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL1237591 | 1.00 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL5013150 | 1.00 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL30167868 | 1.00 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL29394982 | 1.00 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL5013147 | 1.00 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL5655025 | 1.00 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL678304 | 0.99 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL41145 | 0.99 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL41146 | 0.99 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | claimed |
| EP-2080511-A2 | Active agent delivery systems and methods for protecting and administering active agents | Shire LLC (US) | 2009-07-22 | — | — | EP | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| EP-1968978-A2 | FORMS OF DOLASETRON MESYLATE AND PROCESSES FOR THEIR PREPARATION | Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság (HU) | 2008-09-17 | — | — | EP | claimed |
| EP-1968588-A2 | CRYSTALLINE FORMS OF DOLASETRON BASE AND PROCESSES FOR PREPARATION THEREOF | TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság (HU) | 2008-09-17 | — | — | EP | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20070203176-A1 | Crystalline forms of dolasetron base and processes for preparation thereof | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-08-30 | — | — | US | claimed |
| US-20070203177-A1 | Forms of dolasetron mesylate and processes for their preparation | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-08-30 | — | — | US | claimed |
| WO-2007081907-A2 | CRYSTALLINE FORMS OF DOLASETRON BASE AND PROCESSES FOR PREPARATION THEREOF | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-07-19 | — | — | WO | claimed |
| WO-2007081909-A2 | FORMS OF DOLASETRON MESYLATE AND PROCESSES FOR THEIR PREPARATION | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO (HU) | 2007-07-19 | — | — | WO | claimed |
| CN-1629161-A | Methane sulfonic acid dolasetron crystallographic form and its preparation method | CHENGDU XINJIE HI TECH DEV CO (CN) | 2005-06-22 | — | — | CN | claimed |
| CN-118772190-A | Synthesis method of 1-methyl-5- (2-trimethylsilyl picolyl) indole compound | 南京工业大学 | 2024-10-15 | — | — | CN | disclosed |
| CN-110719778-B | Compositions and methods for treating depression | 才思治疗公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240123168-A1 | PRODUCT DELIVERY DEVICES AND METHODS | MUSTAPHA JIHAD A (US) | 2024-04-18 | — | — | US | disclosed |
| US-11896582-B2 | Use and composition for treating myasthenia gravis and other myasthenic syndromes | DAS-MG, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| CN-1629161-A | Methane sulfonic acid dolasetron crystallographic form and its preparation method | CHENGDU XINJIE HI TECH DEV CO (CN) | 2005-06-22 | — | — | CN | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1490090-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | New River Pharmaceuticals Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003079972-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PARMACEUTICALS INC. (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203177-A1 | Forms of dolasetron mesylate and processes for their preparation | DDOST, DAD1, TYMP | HTR3A 257/4885KCNH2 1372/4885SLC6A4 307/4885 |
| US-20070203176-A1 | Crystalline forms of dolasetron base and processes for preparation thereof | DAD1, DDOST, ALG8 | HTR3A 871/4885KCNH2 1149/4885SLC6A4 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.